



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 April 2017
EMA/CHMP/76823/2017
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (initial authorisation)

Riximyo rituximab

On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Riximyo, intended for the treatment of non-Hodgkin's lymphoma (NHL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The applicant for this medicinal product is Sandoz GmbH.

Riximyo will be available as a 500-mg and as a 100-mg concentrate for solution for infusion. The active substance of Riximyo is rituximab, a monoclonal antibody (ATC code: L01XC02) that binds specifically to the transmembrane protein CD20 found on both malignant and normal B cells. In NHL this promotes destruction of malignant B cells and thus controls tumour growth. In RA, GPA and MPA, it reduces B cells involved in their pathogenesis.

Riximyo is a biological medicinal product that is highly similar to the reference product Mabthera (rituximab), which was authorised in the EU on 2 June 1998. Studies have shown Riximyo to have comparable quality, safety and efficacy to Mabthera.

The full indications are:

“Non-Hodgkin's lymphoma (NHL)

Riximyo is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.

Riximyo maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

Riximyo monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy.

Riximyo is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion



prednisolone) chemotherapy.

Rheumatoid arthritis

Riximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.

Riximyo has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

Granulomatosis with polyangiitis and microscopic polyangiitis

Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA)."

It is proposed that Riximyo be administered under the close supervision of an experienced healthcare professional and in an environment where full resuscitation facilities are immediately available.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.